{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:37:01Z","timestamp":1787236621853,"version":"build-2736575974"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Open Science"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.euros.2026.02.008","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T13:14:57Z","timestamp":1771852497000},"page":"47-55","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Oncological Outcomes of Epirubicin-based Hyperthermic Intravesical Chemotherapy in Bacillus Calmette-Gu\u00e9rin (BCG)-na\u00efve Patients and Patients with BCG Failure: A Multicenter Retrospective Observational Study"],"prefix":"10.1016","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-4122-8249","authenticated-orcid":false,"given":"Nicolas","family":"Arnold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Koneval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Blanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Lucca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihai Dorin","family":"Vartolomei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila","family":"Schneidewind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Giudici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George N.","family":"Thalmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Kiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beat","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euros.2026.02.008_b0005","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1007\/s00345-019-02984-4","article-title":"The global burden of urinary bladder cancer: an update","volume":"38","author":"Richters","year":"2020","journal-title":"World J Urol"},{"issue":"6 Suppl 1","key":"10.1016\/j.euros.2026.02.008_b0010","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.urology.2005.07.062","article-title":"Bladder cancer: epidemiology, staging and grading, and diagnosis","volume":"66","author":"Kirkali","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.euros.2026.02.008_b0015","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2026.02.008_b0020","series-title":"EAU guidelines on non-muscle-invasive bladder cancer (TaT1 and CIS)","author":"Gontero","year":"2025"},{"key":"10.1016\/j.euros.2026.02.008_b0025","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","article-title":"An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Gu\u00e9rin for non\u2013muscle-invasive bladder cancer","volume":"56","author":"Malmstr\u00f6m","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2026.02.008_b0030","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1464-410X.2003.04655.x","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials","volume":"93","author":"Shelley","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.euros.2026.02.008_b0035","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0022-5347(05)64043-8","article-title":"Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity","volume":"169","author":"B\u00f6hle","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.euros.2026.02.008_b0040","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.juro.2016.12.090","article-title":"Intravesical therapy for the treatment of nonmuscle invasive bladder cancer: a systematic review and meta-analysis","volume":"197","author":"Chou","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.euros.2026.02.008_b0045","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1586\/era.09.35","article-title":"Definition and management of patients with bladder cancer who fail BCG therapy","volume":"9","author":"Martin","year":"2009","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.euros.2026.02.008_b0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.urolonc.2021.09.022","article-title":"Critical shortage in BCG immunotherapy: how did we get here and where will it take us?","volume":"40","author":"Harvey","year":"2022","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euros.2026.02.008_b0055","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S0022-5347(17)37316-0","article-title":"Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer","volume":"147","author":"Lamm","year":"1992","journal-title":"J Urol"},{"key":"10.1016\/j.euros.2026.02.008_b0060","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/bju.13088","article-title":"Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer","volume":"117","author":"Cockerill","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.euros.2026.02.008_b0065","first-page":"126","article-title":"Intravesical gemcitabine as bladder-preserving treatment for BCG unresponsive non-muscle-invasive bladder cancer. Results from a single-arm, open-label study. BJUI","volume":"1","author":"Hurle","year":"2020","journal-title":"Compass"},{"key":"10.1016\/j.euros.2026.02.008_b0070","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/j.1464-410X.2009.08543.x","article-title":"A single-institution experience with induction and maintenance intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to bacille Calmette-Gu\u00e9rin therapy","volume":"104","author":"Barlow","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.euros.2026.02.008_b0075","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0022-5347(05)67799-3","article-title":"Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder","volume":"163","author":"Steinberg","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.euros.2026.02.008_b0080","article-title":"Intravesical gemcitabine for non-muscle invasive bladder cancer","volume":"2021","author":"Han","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.euros.2026.02.008_b0085","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3233\/BLC-160084","article-title":"Efficacy of Mycobacterium phlei cell wall-nucleic acid complex (MCNA) in BCG-unresponsive patients","volume":"3","author":"Li","year":"2017","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.euros.2026.02.008_b0090","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.juro.2014.09.109","article-title":"Efficacy and safety of MCNA in patients with nonmuscle invasive bladder cancer at high risk for recurrence and progression after failed treatment with bacillus Calmette-Gu\u00e9rin","volume":"193","author":"Morales","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.euros.2026.02.008_b0095","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.urolonc.2005.11.026","article-title":"Final results from a national multicenter phase II trial of combination bacillus Calmette-Gu\u00e9rin plus interferon \u03b1-2B for reducing recurrence of superficial bladder cancer","volume":"24","author":"Joudi","year":"2006","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euros.2026.02.008_b0100","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.euo.2025.03.007","article-title":"Oncological outcomes in bacillus Calmette-Gu\u00e9rin\u2013na\u00efve high-risk non-muscle-invasive bladder cancer patients: a systematic review on current treatment strategies and future perspectives","volume":"8","author":"Longoni","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euros.2026.02.008_b0105","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/S0022-5347(01)63728-5","article-title":"Local microwave hyperthermia and intravesical chemotherapy as bladder sparing treatment for select multifocal and unresectable superficial bladder tumors","volume":"159","author":"Colombo","year":"1998","journal-title":"J Urol"},{"key":"10.1016\/j.euros.2026.02.008_b0110","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ucl.2019.09.008","article-title":"Heated intravesical chemotherapy","volume":"47","author":"Tan","year":"2020","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.euros.2026.02.008_b0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/262313","article-title":"Hyperthermia as adjunct to intravesical chemotherapy for bladder cancer","volume":"2013","author":"Owusu","year":"2013","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.euros.2026.02.008_b0120","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S1040-8428(03)00076-3","article-title":"Combination of intravesical chemotherapy and hyperthermia for the treatment of superficial bladder cancer: preliminary clinical experience","volume":"47","author":"Colombo","year":"2003","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.euros.2026.02.008_b0125","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1200\/JCO.2003.01.089","article-title":"Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma","volume":"21","author":"Colombo","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euros.2026.02.008_b0130","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/iju.12639","article-title":"Is thermochemotherapy with the Synergo system a viable treatment option in patients with recurrent non-muscle-invasive bladder cancer?","volume":"22","author":"Kiss","year":"2015","journal-title":"Int J Urol"},{"key":"10.1016\/j.euros.2026.02.008_b0135","unstructured":"US Food and Drug Administration. BCG-unresponsive nonmuscle invasive bladder cancer: developing drugs and biologics for treatment guidance for industry. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/bacillus-calmette-guerin-unresponsive-nonmuscle-invasive-bladder-cancer-developing-drugs-and."},{"key":"10.1016\/j.euros.2026.02.008_b0140","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euros.2026.02.008_b0145","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euros.2026.02.008_b0150","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s00345-015-1595-3","article-title":"Efficacy and safety of a new device for intravesical thermochemotherapy in non-grade 3 BCG recurrent NMIBC: a phase I\u2013II study","volume":"34","author":"Soria","year":"2016","journal-title":"World J Urol"},{"key":"10.1016\/j.euros.2026.02.008_b0155","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.3390\/cancers16071398","article-title":"Hyperthermic intravesical chemotherapy (HIVEC) using epirubicin in an optimized setting in patients with NMIBC recurrence after failed BCG therapy","volume":"16","author":"Blanc","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.euros.2026.02.008_b0160","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.eururo.2021.12.005","article-title":"International Bladder Cancer Group consensus statement on clinical trial design for patients with bacillus Calmette-Gu\u00e9rin\u2013exposed high-risk non\u2013muscle-invasive bladder cancer","volume":"82","author":"Roumigui\u00e9","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2026.02.008_b0165","doi-asserted-by":"crossref","first-page":"245.e19","DOI":"10.1016\/j.urolonc.2024.01.300","article-title":"HIVEC as an alternative option in non-muscle-invasive bladder cancer: experiences from a high-volume center","volume":"42","author":"Kastner","year":"2024","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euros.2026.02.008_b0170","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1007\/s00345-023-04332-z","article-title":"Efficacy of hyperthermic intravesical chemotherapy (HIVEC) in patients with non-muscle invasive bladder cancer after BCG failure","volume":"41","author":"Pignot","year":"2023","journal-title":"World J Urol"},{"key":"10.1016\/j.euros.2026.02.008_b0175","first-page":"287","article-title":"Outcomes and complications of hyperthermic intravesical chemotherapy using mitomycin C or epirubicin for patients with non-muscle invasive bladder cancer after bacillus Calmette-Gu\u00e9rin treatment failure","volume":"73","author":"Chiancone","year":"2020","journal-title":"Cent Eur J Urol"},{"key":"10.1016\/j.euros.2026.02.008_b0180","doi-asserted-by":"crossref","first-page":"377","DOI":"10.3390\/cancers13030377","article-title":"Long-term experience with radiofrequency-induced hyperthermia combined with intravesical chemotherapy for non-muscle invasive bladder cancer","volume":"13","author":"Brummelhuis","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.euros.2026.02.008_b0185","doi-asserted-by":"crossref","first-page":"62.e13","DOI":"10.1016\/j.urolonc.2021.07.019","article-title":"Long-term efficacy of hyperthermic intravesical chemotherapy for BCG-unresponsive non-muscle invasive bladder cancer","volume":"40","author":"Pijpers","year":"2022","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euros.2026.02.008_b0190","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.eururo.2010.05.041","article-title":"Do patients benefit from routine follow-up to detect recurrences after radical cystectomy and ileal orthotopic bladder substitution?","volume":"58","author":"Giannarini","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2026.02.008_b0195","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3233\/BLC-150008","article-title":"Sequential intravesical gemcitabine and docetaxel for the salvage treatment of non-muscle invasive bladder cancer","volume":"1","author":"Steinberg","year":"2015","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.euros.2026.02.008_b0200","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1097\/JU.0000000000000688","article-title":"Multi-institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer","volume":"203","author":"Steinberg","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.euros.2026.02.008_b0205","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/JU.0000000000002740","article-title":"Sequential intravesical gemcitabine and docetaxel for bacillus Calmette-Gu\u00e9rin-na\u00efve high-risk nonmuscle-invasive bladder cancer","volume":"208","author":"McElree","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.euros.2026.02.008_b0210","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.euf.2018.08.019","article-title":"Systematic review on the utilization of maintenance intravesical chemotherapy in the management of non\u2013muscle-invasive bladder cancer","volume":"4","author":"Tabayoyong","year":"2018","journal-title":"Eur Urol Focus"}],"container-title":["European Urology Open Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266616832600042X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266616832600042X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T11:25:35Z","timestamp":1774869935000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266616832600042X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":42,"alternative-id":["S266616832600042X"],"URL":"https:\/\/doi.org\/10.1016\/j.euros.2026.02.008","relation":{},"ISSN":["2666-1683"],"issn-type":[{"value":"2666-1683","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oncological Outcomes of Epirubicin-based Hyperthermic Intravesical Chemotherapy in Bacillus Calmette-Gu\u00e9rin (BCG)-na\u00efve Patients and Patients with BCG Failure: A Multicenter Retrospective Observational Study","name":"articletitle","label":"Article Title"},{"value":"European Urology Open Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euros.2026.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}